Quetiapine Extended-Release Cannot Be Crushed—Switch to Immediate-Release at Same Total Daily Dose
For a patient on 550 mg quetiapine ER who cannot swallow tablets whole, convert to quetiapine immediate-release 275 mg twice daily (total 550 mg/day). Extended-release formulations must never be crushed, as this destroys the controlled-release mechanism and can lead to dangerous dose dumping 1.
Conversion Strategy
The FDA labeling for quetiapine confirms that immediate-release and extended-release formulations have equivalent bioavailability when given at the same total daily dose 1. Research demonstrates that once-daily quetiapine XR produces similar area under the curve (AUC) and minimum plasma concentration (Cmin) compared to equivalent doses of quetiapine IR given twice daily 2, 3.
Direct 1:1 conversion approach:
- Current dose: 550 mg ER once daily
- Convert to: 275 mg IR twice daily (morning and evening)
- Total daily dose remains 550 mg
Dosing Schedule
Quetiapine immediate-release should be administered twice daily (every 12 hours) 4, 1. The FDA labeling specifies that IR formulations are typically dosed in divided doses 2-3 times daily, with twice-daily dosing being standard for maintenance therapy 1.
Practical dosing:
- 275 mg in the morning
- 275 mg at bedtime
If 275 mg tablets are not available, use combination of available strengths (e.g., 200 mg + 50 mg + 25 mg).
Important Safety Considerations
Monitor closely during the first week after conversion. While the total daily exposure should be equivalent, the immediate-release formulation produces:
- Higher peak plasma concentrations (Cmax approximately 13% higher) 3
- Earlier time to peak (2 hours vs 5 hours) 3
- More variable plasma levels throughout the day 2
This means the patient may experience:
- Increased sedation in the first 2-4 hours after each dose
- More pronounced orthostatic hypotension risk, particularly with the morning dose
- Potential for increased dizziness 4
Mitigation strategies:
- Consider giving the larger portion of the dose at bedtime if daytime sedation becomes problematic (e.g., 200 mg morning, 350 mg bedtime)
- Advise patient to take morning dose with food to potentially reduce peak concentration effects
- Counsel about fall risk, especially in elderly patients 4
Special Population Adjustments
If your patient is elderly or frail, the FDA recommends slower titration and lower target doses 1. However, since this patient is already stable on 550 mg ER, maintain the same total daily dose but monitor more carefully for:
- Orthostatic hypotension (check blood pressure sitting and standing)
- Excessive sedation
- Confusion or delirium 4
If hepatic impairment is present, the current 550 mg dose may already be too high, as quetiapine undergoes extensive hepatic metabolism 1. Consider dose reduction and monitor closely.
Alternative Administration Routes
If the patient truly cannot take oral tablets in any form, quetiapine has no parenteral formulation available 4. The guidelines explicitly state "oral route only" for quetiapine 4. Unlike some antipsychotics (haloperidol, olanzapine), quetiapine cannot be given subcutaneously, intramuscularly, or intravenously.
If oral administration is impossible, you must switch to a different antipsychotic with parenteral options (e.g., haloperidol, olanzapine) 4.
Common Pitfall to Avoid
Never crush extended-release tablets. This is a critical medication error that can result in:
- Immediate release of the entire dose
- Toxic peak plasma levels
- Severe sedation, hypotension, or respiratory depression
- Loss of therapeutic effect later in the dosing interval
The extended-release matrix is specifically designed to control drug release over 24 hours 2, 3. Crushing destroys this mechanism entirely.